<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35266128</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of general internal medicine</Title><ISOAbbreviation>J Gen Intern Med</ISOAbbreviation></Journal><ArticleTitle>Association of Vaccination with the Persistence of Post-COVID Symptoms.</ArticleTitle><Pagination><StartPage>1748</StartPage><EndPage>1753</EndPage><MedlinePgn>1748-1753</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11606-022-07465-w</ELocationID><Abstract><AbstractText Label="BACKGROUND">Patients who have had COVID-19 often report persistent symptoms after resolution of their acute illness. Recent reports suggest that vaccination may be associated with improvement in post-acute symptoms. We used data from a prospective cohort to assess differences in post-acute sequelae of COVID (PASC) among vaccinated vs. unvaccinated patients.</AbstractText><AbstractText Label="METHODS">We used data from a cohort of COVID-19 patients enrolled into a prospective registry established at a tertiary care health system in New York City. Participants underwent a baseline evaluation before COVID-19 vaccines were available and were followed 6 months later. We compared unadjusted and propensity score-adjusted baseline to 6-month change for several PASC-related symptoms and measures: anosmia, respiratory (cough, dyspnea, phlegm, wheezing), depression, anxiety, post-traumatic stress disorder (PTSD; COVID-19-related and other trauma), and quality-of-life domains among participants who received vs. those who did not receive COVID-19 vaccination.</AbstractText><AbstractText Label="RESULTS">The study included 453 COVID-19 patients with PASC, of which 324 (72%) were vaccinated between the baseline and 6-month visit. Unadjusted analyses did not show significant differences in the baseline to 6-month change in anosmia, respiratory symptoms, depression, anxiety, PTSD, or quality of life (p &gt; 0.05 for all comparisons) among vaccinated vs. unvaccinated patients. Similar results were found in propensity-adjusted comparisons and in secondary analyses based on the number of vaccine doses received.</AbstractText><AbstractText Label="CONCLUSIONS">Our findings suggest that COVID vaccination is not associated with improvement in PASC. Additional studies are needed to better understand the mechanisms underlying PASC and to develop effective treatments.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s) under exclusive licence to Society of General Internal Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wisnivesky</LastName><ForeName>Juan P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Govindarajulu</LastName><ForeName>Usha</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Population Health and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bagiella</LastName><ForeName>Emilia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Population Health and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goswami</LastName><ForeName>Ruchir</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kale</LastName><ForeName>Minal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Kirk N</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meliambro</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zijian</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Endocrinology, Diabetes and Bone Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aberg</LastName><ForeName>Judith A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Jenny J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0001-7104-8480</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. jenny.lin@mssm.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Gen Intern Med</MedlineTA><NlmUniqueID>8605834</NlmUniqueID><ISSNLinking>0884-8734</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086582" MajorTopicYN="N">Anosmia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID vaccination</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of COVID</Keyword><Keyword MajorTopicYN="N">symptoms</Keyword></KeywordList><CoiStatement>Dr. Wisnivesky received consulting honorarium from Atea, Sanofi, PPD, and Banook and grants from Sanofi, Arnold Consulting, and Regeneron. Dr. Aberg reports grants from Atea, Emergent Biosolutions, Frontier Technologies, Gilead Sciences, Glaxo Smith Kline, Janssen, Merck, Pfizer, Regeneron, and Viiv Healthcare and consulting honorarium from Glaxo Smith Kline and Merck. The other authors report no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>10</Day><Hour>5</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35266128</ArticleId><ArticleId IdType="pmc">PMC8906626</ArticleId><ArticleId IdType="doi">10.1007/s11606-022-07465-w</ArticleId><ArticleId IdType="pii">10.1007/s11606-022-07465-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lerner AM, Robinson DA, Yang L, et al. Toward Understanding COVID-19 Recovery: National Institutes of Health Workshop on Postacute COVID-19. Ann Intern Med. Published online March 30, 2021. 10.7326/M21-1043</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8025940</ArticleId><ArticleId IdType="pubmed">33780290</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue JK, Franko NM, McCulloch DJ, et al. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw Open. 2021;4(2):e210830. doi: 10.1001/jamanetworkopen.2021.0830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0830</ArticleId><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall S, Rosell A, Phillipson M, et al. Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. JAMA. 2021;325(19):2015&#x2013;2016. doi: 10.1001/jama.2021.5612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.5612</ArticleId><ArticleId IdType="pmc">PMC8027932</ArticleId><ArticleId IdType="pubmed">33825846</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet Lond Engl. 2021;397(10270):220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81(6):e4&#x2013;e6. doi: 10.1016/j.jinf.2020.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.029</ArticleId><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(30):993&#x2013;998. doi: 10.15585/mmwr.mm6930e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6930e1</ArticleId><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324(6):603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein L, Guarino B. Some long-haul covid-19 patients say their symptoms are subsiding after getting vaccines. Washington Post. https://www.washingtonpost.com/health/long-haul-covid-vaccine/2021/03/16/6effcb28-859e-11eb-82bc-e58213caa38e_story.html. Published March 16, 2021. Accessed June 21, 2021.</Citation></Reference><Reference><Citation>Stone W. Mysterious Ailment, Mysterious Relief: Vaccines Help Some COVID Long-Haulers. NPR.org. Published March 31, 2021. Accessed June 21, 2021. https://www.npr.org/sections/health-shots/2021/03/31/982799452/mysterious-ailment-mysterious-relief-vaccines-help-some-covid-long-haulers</Citation></Reference><Reference><Citation>Lovelace Jr B. Some people with &#x201c;long Covid&#x201d; say their symptoms ease after getting vaccine. CNBC. Published April 7, 2021. Accessed June 21, 2021. https://www.cnbc.com/2021/04/07/covid-vaccine-long-haulers-report-symptoms-easing-after-getting-shot.html</Citation></Reference><Reference><Citation>Arnold DT, Milne A, Samms E, Stadon L, Maskell NA, Hamilton FW. Are vaccines safe in patients with Long COVID? A prospective observational study. medRxiv. Published online March 14, 2021:2021.03.11.21253225. 10.1101/2021.03.11.21253225</Citation></Reference><Reference><Citation>National Health Interview Survey (NHIS). Published June 2, 2021. Accessed June 21, 2021. https://www.cdc.gov/nchs/nhis/index.htm</Citation></Reference><Reference><Citation>PhenX Toolkit: Covid19. Published February 22, 2021. Accessed June 21, 2021. https://www.phenxtoolkit.org/covid19</Citation></Reference><Reference><Citation>Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581&#x2013;586. doi: 10.1136/thx.54.7.581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.54.7.581</ArticleId><ArticleId IdType="pmc">PMC1745516</ArticleId><ArticleId IdType="pubmed">10377201</ArticleId></ArticleIdList></Reference><Reference><Citation>Manali ED, Lyberopoulos P, Triantafillidou C, et al. MRC chronic Dyspnea Scale: Relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study. BMC Pulm Med. 2010;10:32. doi: 10.1186/1471-2466-10-32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2466-10-32</ArticleId><ArticleId IdType="pmc">PMC2893122</ArticleId><ArticleId IdType="pubmed">20509928</ArticleId></ArticleIdList></Reference><Reference><Citation>Barr JT, Schumacher GE, Freeman S, LeMoine M, Bakst AW, Jones PW. American translation, modification, and validation of the St. George&#x2019;s Respiratory Questionnaire. Clin Ther. 2000;22(9):1121&#x2013;1145. doi: 10.1016/S0149-2918(00)80089-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0149-2918(00)80089-2</ArticleId><ArticleId IdType="pubmed">11048909</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson CB, Jones PW, O&#x2019;Leary CJ, Cole PJ, Wilson R. Validation of the St. George&#x2019;s Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med. 1997;156(2 Pt 1):536&#x2013;541. doi: 10.1164/ajrccm.156.2.9607083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.156.2.9607083</ArticleId><ArticleId IdType="pubmed">9279236</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Strine TW, Spitzer RL, Williams JBW, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114(1-3):163&#x2013;173. doi: 10.1016/j.jad.2008.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2008.06.026</ArticleId><ArticleId IdType="pubmed">18752852</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;we B, Decker O, M&#xfc;ller S, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care. 2008;46(3):266&#x2013;274. doi: 10.1097/MLR.0b013e318160d093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e318160d093</ArticleId><ArticleId IdType="pubmed">18388841</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer RL, Kroenke K, Williams JBW, L&#xf6;we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092&#x2013;1097. doi: 10.1001/archinte.166.10.1092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.166.10.1092</ArticleId><ArticleId IdType="pubmed">16717171</ArticleId></ArticleIdList></Reference><Reference><Citation>Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation. J Trauma Stress. 2015;28(6):489&#x2013;498. doi: 10.1002/jts.22059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jts.22059</ArticleId><ArticleId IdType="pubmed">26606250</ArticleId></ArticleIdList></Reference><Reference><Citation>Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol. 2010;63(11):1179&#x2013;1194. doi: 10.1016/j.jclinepi.2010.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2010.04.011</ArticleId><ArticleId IdType="pmc">PMC2965562</ArticleId><ArticleId IdType="pubmed">20685078</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook KF, Jensen SE, Schalet BD, et al. PROMIS measures of pain, fatigue, negative affect, physical function, and social function demonstrated clinical validity across a range of chronic conditions. J Clin Epidemiol. 2016;73:89&#x2013;102. doi: 10.1016/j.jclinepi.2015.08.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2015.08.038</ArticleId><ArticleId IdType="pmc">PMC5131708</ArticleId><ArticleId IdType="pubmed">26952842</ArticleId></ArticleIdList></Reference><Reference><Citation>Hays RD, Spritzer KL, Schalet BD, Cella D. PROMIS&#xae;-29 v2.0 profile physical and mental health summary scores. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2018;27(7):1885&#x2013;1891. doi: 10.1007/s11136-018-1842-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-018-1842-3</ArticleId><ArticleId IdType="pmc">PMC5999556</ArticleId><ArticleId IdType="pubmed">29569016</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Scordo KA, Richmond MM, Munro N. Post-COVID-19 Syndrome: Theoretical Basis, Identification, and Management. AACN Adv Crit Care. Published online May 4, 2021:e1-e8. 10.4037/aacnacc2021492</Citation><ArticleIdList><ArticleId IdType="pubmed">33942071</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639&#x2013;644. doi: 10.1038/s41586-021-03207-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585. doi: 10.1126/science.abd4585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva Andrade B, Siqueira S, de Assis Soares WR, et al. Long-COVID and Post-COVID Health Complications: An Up-to-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms. Viruses. 2021;13(4):700. doi: 10.3390/v13040700.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13040700</ArticleId><ArticleId IdType="pmc">PMC8072585</ArticleId><ArticleId IdType="pubmed">33919537</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuyama M, Ladinsky MS, Jha D, et al. 785 SARS CoV-2 infects enterocytes in vivo and can persist up to 7 months following resolution of symptoms. Gastroenterology. 2021;160(6):S-159. doi: 10.1016/S0016-5085(21)01130-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0016-5085(21)01130-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Doykov I, H&#xe4;llqvist J, Gilmour KC, Grandjean L, Mills K, Heywood WE. &#x201c;The long tail of Covid-19&#x201d; - The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Research. 2020;9:1349. doi: 10.12688/f1000research.27287.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.27287.2</ArticleId><ArticleId IdType="pmc">PMC7745182</ArticleId><ArticleId IdType="pubmed">33391730</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Fogarty H, Dyer A, et al. Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. J Thromb Haemost JTH. 2021;19(4):1064&#x2013;1070. doi: 10.1111/jth.15267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15267</ArticleId><ArticleId IdType="pmc">PMC8013297</ArticleId><ArticleId IdType="pubmed">33587810</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, et al. Functional autoantibodies against G protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100. doi: 10.1016/j.jtauto.2021.100100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021;20(4):102792. doi: 10.1016/j.autrev.2021.102792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102792</ArticleId><ArticleId IdType="pmc">PMC7892316</ArticleId><ArticleId IdType="pubmed">33610751</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>